Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
8.07
+0.07 (0.88%)
Apr 22, 2025, 12:14 PM EDT - Market open
Immunome Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Immunome stock have an average target of 26, with a low estimate of 21 and a high estimate of 33. The average target predicts an increase of 222.18% from the current stock price of 8.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +185.01% | Apr 2, 2025 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +308.92% | Mar 20, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $30 | Buy | Reiterates | $30 | +271.75% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $35 → $25 | Strong Buy | Maintains | $35 → $25 | +209.79% | Mar 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +160.22% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
1.31M
from 9.04M
Decreased by -85.50%
Revenue Next Year
17.82M
from 1.31M
Increased by 1,259.12%
EPS This Year
-2.82
from -5.00
EPS Next Year
-3.03
from -2.82
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.5M | 54.6M | 161.2M | ||
| Avg | 1.3M | 17.8M | 76.4M | ||
| Low | n/a | n/a | 46.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5% | 4,064.8% | 804.6% | ||
| Avg | -85.5% | 1,259.1% | 328.7% | ||
| Low | - | - | 158.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.95 | -1.89 | -1.42 | ||
| Avg | -2.82 | -3.03 | -2.77 | ||
| Low | -3.87 | -4.16 | -3.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.